title: Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial.
abstract: BACKGROUND
  Omega-3 polyunsaturated fatty acids (n-3 PUFA) have been reported to reduce the risk of sudden cardiac death presumed to be due to fatal ventricular arrhythmias, but their effect on atrial arrhythmias is unclear.
  
  
  RESULTS
  Patients (n=108) undergoing coronary artery bypass graft surgery were randomly assigned to receive 2 g/d n-3 PUFA or placebo (olive oil) for at least 5 days before surgery (median, 16 days; range, 12 to 21 days). Phospholipid n-3 PUFA were measured in serum at study entry and at surgery and in right atrial appendage tissue at surgery. Echocardiography was used to assess left ventricular function and left atrial dimensions. Postoperative continuous ECG monitoring (Lifecard CF) for 5 days or until discharge, if earlier, was performed with a daily 12-lead ECG and clinical review if patients remained in the hospital beyond 5 days. Lifecard recordings were analyzed for episodes of atrial fibrillation (AF) > or =30 seconds (primary outcome). Clinical AF, AF burden (% time in AF), hospital stay, and intensive care/high dependency care stay were measured as secondary outcomes. One hundred three patients completed the study (51 in the placebo group and 52 in the n-3 PUFA group). There were no clinically relevant differences in baseline characteristics between groups. n-3 PUFA levels were higher in serum and right atrial tissue in the active treatment group. There was no significant difference between groups in the primary outcome of AF (95% confidence interval [CI], -6% to 30%, P=0.28) in any of the secondary outcomes or in AF-free survival.
  
  
  CONCLUSIONS
  Omega-3 PUFA do not reduce the risk of AF after coronary artery bypass graft surgery. Clinical Trial Registration- www.ukcrn.org.uk. Identifier: 4437.
authors.affiliation: University of Manchester, Manchester, United Kingdom. palaniappan.saravanan@manchester.ac.uk
authors.forename: Palaniappan
authors.initials: P
authors.lastname: Saravanan
authors.forename: Ben
authors.initials: B
authors.lastname: Bridgewater
authors.forename: Annette L
authors.initials: AL
authors.lastname: West
authors.forename: Stephen C
authors.initials: SC
authors.lastname: O'Neill
authors.forename: Philip C
authors.initials: PC
authors.lastname: Calder
authors.forename: Neil C
authors.initials: NC
authors.lastname: Davidson
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000209:etiology / Q000517:prevention & control*; D002097:C-Reactive Protein / Q000032:analysis; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D004311:Double-Blind Method; D004452:Echocardiography; D004562:Electrocardiography; D015525:Fatty Acids, Omega-3 / Q000032:analysis / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D006325:Heart Atria / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D011300:Preoperative Care
chemical_list: D015525:Fatty Acids, Omega-3; D002097:C-Reactive Protein